Japanese-based Shionogi has partnered with public institutions, academia and other companies to develop potential drugs and vaccine against Covid-19.
The company formed a research alliance with the Hokkaido University Research Center for Zoonosis Control to discover new therapeutic candidates.
They discovered multiple promising lead compounds during in-house in-vitro studies. Shionogi is expediting drug discovery efforts to potentially launch clinical trials later this year.
The company aims to develop effective compounds against Covid-19 infection, which could possibly be a long-lasting outbreak.